Story
Molly, Philip, Jay and I (Sam) will be running the Royal Parks Half Marathon on Sunday 13 October 2024 in support of the ICR charity, funding cancer research at the institute. The following is a short bio summarising the work of those involved and the strategy of the institute.
Cancer is a highly complex disease with more than 200 types, each caused by a different combination of genetic defects. Even among patients with a single type of cancer, such as breast or lung cancer, the genetic triggers vary from one person to the next. At The Institute of Cancer Research, London, we believe it is important to take into account those differences as we discover new cancer treatments – an approach known as personalised medicine.
Guided by our research strategy, we lead in studying cancer-related biological processes, particularly those preserving genome integrity. Our goal is to understand how these processes fail in cancer and develop treatments that exploit this instability. With access to cutting-edge facilities and techniques, our findings directly support our drug discovery program, paving the way for future cancer treatment innovations.
The ICR and The Royal Marsden have worked together on a joint strategy for world-class cancer research – motivated by the ambition of offering a long and healthy life for everyone affected by cancer.